Senhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination
TAIPEI and SAN DIEGO, May 5, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced the initiation of a global, multi-center clinical trial. The Company has also submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), marking a key milestone...
IHH Healthcare Unifies Enterprise Systems with Oracle Fusion Cloud Applications to Strengthen Care Delivery Across Markets
Multinational integrated healthcare provider plans to consolidate multiple enterprise systems onto single AI-enabled cloud platform to boost productivity, cost efficiency and patient-centred care SINGAPORE, May 5, 2026 /PRNewswire/ -- IHH Healthcare (IHH), one of the world's largest integrated healthcare providers, has selected Oracle Fusion Cloud Applications across its enterprise finance, human resource (HR)...
Cleveland Clinic, RIKEN, and IBM Model a 12,635-Atom Protein – the Largest Known to Be Simulated with Quantum Computers
Milestone simulation of biologically meaningful molecules expands quantum-centric supercomputing's role as a scientific tool YORKTOWN HEIGHTS, N.Y. and CLEVELAND, May 5, 2026 /PRNewswire/ -- Scientists at Cleveland Clinic, RIKEN, and IBM (NYSE: IBM) have used IBM quantum computers and two of the world's most powerful supercomputers to simulate protein complexes spanning up to 12,635 atoms. These are the largest-known simulations...
Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)
Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf Treg therapy, in patients with steroid-refractory GVHD HOUSTON, May 5, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical stage biotechnology company, pioneering allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced that the U.S. Food and Drug...
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
MELBOURNE, Australia and INDIANAPOLIS, Ind., May 5, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology, demonstrating that TLX250‑Px (Zircaix®, 89Zr-girentuximab) PET/CT imaging may be highly predictive of renal malignancy across all subtypes,...
CARiNG Pharmacy Introduces “Empowering Women, Inspiring Wellness” Campaign to Encourage Women to be More Proactive About Their Health
The new campaign focuses on a holistic approach to women's health by connecting inner wellness, outer wellbeing and mental health in everyday life KUALA LUMPUR, Malaysia, May 4, 2026 /PRNewswire/ -- CARiNG Pharmacy, together with Georgetown Pharmacy and Wellings Pharmacy under BIG CARING Group, has launched the "Empowering Women, Inspiring Wellness" campaign, a long-term initiative aimed at encouraging women...
TEN-YEAR PIVOTAL DATA REINFORCE THE LONG-TERM DURABILITY OF EDWARDS’ RESILIA TISSUE
SINGAPORE, May 4, 2026 /PRNewswire/ -- Edwards Lifesciences, the leading global structural heart innovation company, recently announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting. Valvular heart disease...
XtalPi -Enabled PharmaEngine PEP08 Achieves Enrollment Milestone, with Second Synthetic Lethality Program Underway
SHENZHEN, China, May 4, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical...
139th Canton Fair Phase 3 Advances Toward a Better Life with New and Strengthened Product Zones
GUANGZHOU, China, May 3, 2026 /PRNewswire/ -- The 139th China Import and Export Fair (Canton Fair) has rolled out nine newly established product zones. Phase 3 features an expanded and upgraded Intelligent Healthcare zone and the inaugural presentation of a Functional & Technical Fabrics zone. The upgraded Intelligent Healthcare zone brings together...
Restore Vision Announces First-in-Human Clinical Interim Results for RV-001, a GPCR-Based Optogenetic Gene Therapy
Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key May 2026 meetings: Eyecelerator and Retinal Therapeutics Innovation Summit. No dose-limiting toxicities (DLTs) or drug-related serious adverse events (SAEs) have been reported within the scope of this interim analysis, to date in either...
